Abstract

Mutations of the Cell Division Cycle 73 (CDC73) tumor suppressor gene (previously known as HRPT2), encoding for parafibromin, are associated with the Hyperparathyroidism-Jaw Tumor (HPT-JT) syndrome, an autosomal dominant disease whose clinical manifestations are mainly parathyroid tumors and, less frequently, ossifying fibromas of the jaws, uterine and renal tumors. Most mutations of CDC73 are nonsense or frameshift, while missense mutations are rare and generally affect the N-terminal domain of parafibromin, a region that is still poorly characterized. The aim of this study was to characterize a novel somatic CDC73 missense mutation (Ile60Asn) identified in the mandibular tumor of a HPT-JT patient carrying a germline CDC73 inactivating mutation. Immunostaining of the tumor showed reduced nuclear parafibromin immunoreactivity. Western blotting and confocal microscopy of transfected cells demonstrated that the Ile60Asn mutant parafibromin was less expressed than the wild-type protein and exhibited impaired nucleolar localization. Treatment of transfected cells with translation and proteasome inhibitors demonstrated a decreased stability of the Ile60An mutant, partially due to an increase in proteasomal degradation. Overexpression of the Ile60Asn mutant led to increased cell proliferation and to accumulation in the G2/M phase of cell cycle. Moreover, mutant parafibromin lost the ability to down-regulate c-myc expression. In conclusion, our study shows that a missense mutation in the N-terminus of parafibromin, identified in an ossifying fibroma from a HPT-JT patient, stimulated cell proliferation and impaired parafibromin expression and nucleolar localization, suggesting a relevant role of the N-terminal domain for parafibromin function.

Highlights

  • The Hyperparathyroidism-Jaw Tumor (HPT-JT) syndrome is an autosomal dominant disease whose first clinical manifestation is usually the occurrence of parathyroid tumors, that are malignant in 15% of cases; in addition, 25–50% of patients may develop ossifying fibromas of the jaws and benign or malignant renal and uterine tumors [1]

  • We investigated if the Ile60Asn mutant could retain the capability to down-regulate the expression of two parafibromin transcriptional targets, i.e., cyclin D1 and c-myc, involved in the control of cell proliferation

  • This study demonstrated, in an ossifying fibroma of the jaw arising in a HPT-JT patient, the presence of a somatic Cell Division Cycle 73 (CDC73) mutation that probably represented the ‘‘second hit’’ in tumor development, since it led to decreased parafibromin expression and loss of its nucleolar localization

Read more

Summary

Introduction

The Hyperparathyroidism-Jaw Tumor (HPT-JT) syndrome is an autosomal dominant disease whose first clinical manifestation is usually the occurrence of parathyroid tumors, that are malignant in 15% of cases; in addition, 25–50% of patients may develop ossifying fibromas of the jaws and benign or malignant renal and uterine tumors [1]. The ossifying fibromas of mandible and maxilla occurring in HPT-JT patients are histologically distinct from the osteoclastic ‘brown tumors’ typical of primary hyperparathyroidism, and may occur at very early age [1]. CDC73 encodes for parafibromin, a 531 amino acids protein that acts in the context of the RNA polymerase II associated factor 1 (PAF1) transcriptional regulatory complex [3]. The human PAF1 complex associates with RNA polymerase II throughout the entire coding region of transcriptionally active genes, indicating roles in initiation, elongation and post-transcriptional events [2]. Parafibromin has been reported to activate the Wnt signaling through interaction with b-catenin [7] in its dephosphorylated form [8]

Objectives
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.